BioCentury
ARTICLE | Clinical News

ACE527: Phase I data

February 1, 2010 8:00 AM UTC

In a double-blind, placebo-controlled, U.S. Phase I trial in 36 healthy volunteers, ACE527 was well tolerated and induced a mucosal immune response to colonization factors on all 3 strains of E. coli ...